Welcome to EverybodyWiki 😃 ! Nuvola apps kgpg.png Log in or ➕👤 create an account to improve, watchlist or create an article like a 🏭 company page or a 👨👩 bio (yours ?)...

Neuroscience 20 (Brain20, Spine20 and Mental Health20)

From EverybodyWiki Bios & Wiki






The G20 Neuroscience 20 (Brain20, Spine20, and Mental Health20) Established in 2014 as part of building a consortium of International Brain Initiatives and expand brain, spine, and mental health initiative across the G20 nations and beyond. The initiative is Aims to create a global consortium of finest scientists, engineers, physicians, and surgeons to rapidly introduce clinical solutions for neurological disorders, which cost the world economy hundreds of billions of dollars annually. The first G20 World Brain Mapping/neuroscience 20 Summit was launched in 2014 and was sponsored by The Society for Brain Mapping and Therapeutics (SBMT), Brain Mapping Foundation, AMEN clinics, and compumedics.[1][2]

History[edit]

First Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2014[edit]

The first annual summit of the G20 World Brain Mapping and Therapeutics Initiative was held in Brisbane, Australia on November 13th, 2014 in the Mercure Hotel. Sponsored by Amen Clinics, Compumedics Inc, SBMT, and BMF. The Summit commenced with a strong sense and messages of cooperation from U.S. Congressman Chaka Fattah, U.S. Congressman Blumenauer, chairman of the Congressional Neuroscience Caucus, and Kirsty Duncan, Member of the Canadian Parliament .

The program included talks from top US, Italian, Turkish, Australian, and European Brain Mapping Initiative specialists speaking about advanced imaging in diagnosis of Alzheimer's disease, psychiatric disorders, Brain tumors, neurodegenerative affections, Brain Mapping's bid data, current strategies in global clinical trials; as well as, policies that could promote translation, integration and commercialization of advanced technologies and therapeutics like nano-neurosurgery, nano-neuroscience, neuro-trauma, and advances in military medicine. A roundtable discussion with the US and Canadian Policymakerswas also held.[3][4][5][6][7]

.

Second Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2015[edit]

The second annual summit of the G20 World Brain Mapping and Therapeutics Initiative was held in Istanbul, Turkey on November 13th, 2015. Sponsored by the Üsküdar University, Üsküdar University Neuro-Psychiatric Istanbul Hospital and SBMT. The presenters gathered on November 15th, in Antalya where the G20 Summit took part. Prof. Nevzat Tarhan, Rector of Üsküdar University, announced the preliminary report. The finalized report, was published. A trilateral memorandum of Understanding[8] was signed between US-Australia and Turkish scientists focusing on Brain Innovation and Neuro-technologies, which could reduce the cost of healthcare, increase healthcare delivery and create jobs through the formation of biotechnology-pharmaceutical spinoffs.[9][10][11][12][13] SBMT helped with the formulation of the National Photonic Initiative[14]

Third Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2016[edit]

The third Annual G20/N20 World Brain Mapping & Therapeutics (WBMIT) Summit was held on Chongqing, China September 2-4th ,2016.

Science Minister of Canada and Professor of Environmental Studies of the University of Toronto in Canada, on Global collaboration of brain science. The program[15] included talks from top U.S., Chinese, Australian, Turkey Brain Mapping initiative scientists addressing topics such as Neuroscience-20: Global strategic partnership with G20+ nations on Brain Mapping and Therapeutics, A Global Approach to Alzheimer's Disease through N20, Stem cells and biomaterials towards developing a therapy for Parkinson's disease, Getting into the brain. Use of Nanotechnology to cure NeuroAIDS and drug addiction, The Brain and the Human-Bionics Interface: Accelerating healthcare through new global partnerships, High-Resolution MR Neuro Imaging with innovative technology, EEG Entropies, and Mental Illness Relationships, Nano-enabled biosensing systems for neuroHIV managements, Innovative approach to Cancer Therapeutics, Advancing Neuroscience Innovation through N20 and Precise MRI diagnosis on patients with epilepsy.[16] A summary of the convention can be overviewed in the article by Neurosurgery Market Watch, Pages 4-5, and 8.[17][18]N20 formulated IEEE BRAIN initiative and help IEEE to establish its brain initiative[19][14]

Fourth Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2017[edit]

The fourth Annual G20/N20 World Brain Mapping & Therapeutics (WBMIT) Summit was held in Hamburg, Germany.[20]

Uskudar University, the Society for Brain Mapping and Therapeutics (SBMT), Brain Mapping Foundation (BMF), the National Center for NanoBioElectronic (NCNBE) have reunited in Hamburg, Germany during the G20 Summit to increase global cooperation and partnership on clinical and translational neuroscience through the N20 World Brain Mapping Initiative.[21][22]

SPIE and SBMT publish a joint special issue of Brain Mapping and Therapeutics[23]

Fifth Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2018[edit]

The fifth Annual G20/N20 World Brain Mapping & Therapeutics (WBMIT) Summit was held at the Hilton Puerto Madero, Buenos Aires, Argentina, on November 26th - 27th, 2018. It was recognized that the global economic burden of Brain, Spine other nervous systems disorders, amounted to $13 trillion annually.

SBMT and BMF founded the neuroscience-20 t group to create the world's first think-tank for a basic, translational, and clinical neuroscience consisting of physicians, surgeons, researchers, engineers, non-profits, government officials industry leaders, venture philanthropist, and entrepreneurs. In the last five years, N-20 has met its mission and held its meeting in conjunction with the G-20 Leaders' Summit. The Argentinian military jointly co-organized N20 in Argentina.

Mind Eye institute, Uskudar University, MEGIN were sponsors of the Summit.[24][25][26][27]

As an Addition, NASS was invited to be part of the Spine 20[28]

As a direct result of the Summit, four resolutions were convened, and 3 Leader recommendations were agreed upon:

Consensus Recommendations of the Neuroscience-20 Group to the global leaders and Sherpas:[edit]

  • R1. Account for the global economic burden of diseases and injuries of the brain, spine, retina, and peripheral nervous system.
  • R2. Raise awareness to stop the stigmatization of neurological and neuropsychiatric diseases.
  • R3. Close the gaps in access to neurodegenerative disorders and epilepsy care
  • R4. Promote a Whole of government approach to address brain and spine disease and injury (BSDI)

Summary recommendation for the G 20 Leaders:[edit]

  1. Given the cost of neurological disorders to the world economy (> $13 trillion), ensure that N-20 is an integral part of the future G20 Summit and its leadership discussions.
  2. Facilitate global partnership of Brain and Spine research, development, and policy.
  3. Enable the implementation of the N-20 recommendations listed as about.

Sixth Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2019:[edit]

N20 (Brain 20, Spine 20 and Mental Health 20)[edit]

The Summit took place in Osaka, Japan, on June 27th, 2019, where amendments were made to the 2018 N20 resolution.[29]

N20 was coordinated by the SBMT, BMF, European Spine, MEGIN, Chopra Foundation, The Japanese Society for Regeneration Medicine and Rehabilitation (JSRMR), and NASS.[30]

Chairman of the Board of MEGIN, Craig Shapero, was a keynote at the N20 2019[31]

Recommendation for G20 nations to harmonize clinical trials, IRBs, initiatives to fast track introduction of therapeutics and diagnostics.

It was also discussed; how new technologies could reduce the cost of healthcare and increase the efficiency of healthcare delivery globally.

  1. Implementation shall include legislative public and campaigns facilitate innovation in brain (Both neurological and neuropsychiatric) and spine (both cord and column) disorders. We urge that sufficient resources to be allocated as to address growing health burden of brain/spine disorders. Global campaigns using innovative technologies to curb the economic burden. Investment in innovative technologies will reduce the current large cost to global economy.
  2. Efficient delivery of care and faster translation of breakthrough technologies will increase efficiency and decreased financial burdens.[32]
  3. Generate a uniform G20 brain initiative: we urge the G20 to involve national societies, non-profits, NGOs to develop a unified policy.
  4. Improving access to care with predictive analytics and better data collection and dissemination
  5. The committee recommends integration of the techniques to include: advanced diagnostics and therapeutics such as cellular/gene therapy, machine learning, big data, A.I., Biomimetic prosthetic systems, in – Silico modeling, precision/personalized medicine and other technologies with current preventive and therapeutic protocols.
  6. Brain and spine health and fitness: educate patients about exercise and strongly encourage physicians to prescribe appropriate exercises as a therapy in conjunction with current treatments. It will contribute to the prevention of neurological disorders, reduction of comorbidity, as well as improvement of mental and neuropsychiatric health.

At the end of N20/G20 Summit, the following recommendations were drafted for the G20 members and the Sherpas in Osaka Japan June 27 and 28 2019 to prevent low back pain and to prevent disability from low back pain, the number one cause of disability worldwide.

We recommend that the following evidence-based actions be considered to limit the burden of disability related to disorders affecting the spine and the brain:

Public health and prevention of back pain

1. Governments and public health authorities should promote physical activity/exercise education for all to prevent back pain (community location). The physical activity must be adapted to the age, environment, and follow clinical guidelines for exercise. The government should provide an environment to facilitate exercise. The community environment, such as green spaces or facilities to carry out physical activity or exercise, must be provided.

2. Governments and public health authorities should promote exercise for brain and spine health. Healthcare systems should ensure patients have access to supervised exercise programs by qualified, trained health professionals for the treatment of back pain.

3. Governments and health authorities should promote the development of a qualified community– based rehabilitation workforce to enhance the physical activity for spine wellbeing.

4. Implement work in road safety standards and improve emergency response systems.

Treatment of low back pain (primary, secondary and tertiary care)

5. Governments should actively engage in supporting public health campaigns that promote being active, exercise, and education about the causes, course, and cost-effective, evidence-based treatments for back pain.

6. Imaging of the spine within the first three months is not recommended for common low back pain without neurological signs and symptoms.

7. Opioids should only be used according to the Center for disease control (CDC) guidelines

8. We recommend against the use of spine surgery in the absence of evidence-based indications for effectiveness.

9. Evidence-based guidelines should be developed to screen patients who may benefit from spine surgery

10. Governments, health authorities, and civil society should educate the public about the causes course and cost-effective, evidence-based treatments for back pain.

11. Governments and health authorities should develop health policies informed by valid country-specific data and develop systems to collect data if they do not exist.

12. All new spine interventions (surgical and non—surgical) should be evaluated for their effectiveness and cost-effectiveness before implementation in health systems.

13. Relevant providers of spine care should be involved in the development of evidence-based, cost-effective policies for management with spinal disorders.

14. We recommend against the use of ineffective interventions and unnecessary investigations.

15. Most patients with spinal disorders should be managed in primary care settings instead of secondary or tertiary healthcare settings or emergency rooms.

16. We suggest that long-acting non-opioids be used to lower surgical cost inpatients are required spine surgery.

Elderly population in long-term facilities

17. Specific programs, including activation of physical activity for elderly individuals living in long-term facilities, need to be developed for maintaining activity and wellbeing.


Seventh Annual G20/Neuroscience 20 (N20) World Brain Mapping & Therapeutics Summit 2020[edit]

Neuroscience 20 (Brain20, Spine20 and Mental Health20), will be held virtually in November 20th-21st, 2020.[edit]

This year the world has faced a pandemic, SBMT formed a COVID-19 task-force to help find diagnostic methods, treatments, and proper management for this disease. Society for Brain Mapping and Therapeutics (SBMT) 18th president(2020-2021), Dr. Robert Hariri, CEO of Celularity, has received FDA approval for a clinical trial using immunotherapy to treat COVID-19.[33]

The G20 group will allocate over $21 Billion USD to help combat COVID-19.[34]

References[edit]

  1. http://medianet.com.au/releases/release-details?id=814953
  2. "First G20 World Brain Mapping & Therapeutics Scientific Smmit". Unknown parameter |url-status= ignored (help)
  3. "G20 World Brain Mapping Initiative/Summit in Australia started with important messages of Collaboration from Congressman Chaka Fattah, Congressman Earl Blumenauer and Member of the Canadian Parliament Kirsty Duncan and pioneering work by the top G20 scientists" (Press release). Nov 13, 2014.
  4. Oates, Greg (2014-12-17). "Brain Mapping Leader Says Conference Planning Can Change the World". Prevue Meetings & Incentives. Retrieved 2020-06-11.
  5. "G20 World Brain Mapping and Therapeutics Initiative by SBMT will include significant partnership with European Human Brain Project" (Press release). Unknown parameter |url-status= ignored (help)
  6. "Drs. Stecker and Rak To Speak At First G20 World Brain Mapping & Therapeutic Scientific Summit In Australia". Unknown parameter |url-status= ignored (help)
  7. "Why "disorders of the brain" deserve at least equal attention as cardiovascular diseases and cancer". Unknown parameter |url-status= ignored (help)
  8. Therapeutics, Society for Brain Mapping and (2015-11-15), English: SBMT Agreement-2015 N20 (PDF), retrieved 2020-06-10
  9. http://g20brainmapping.uskudar.edu.tr
  10. http://www.worldbrainmapping.org
  11. http://www.uskudar.edu.tr/en/icerik/1098/2-g20-world-brain-mapping-summit-at-uskudar-university
  12. "G20 Istanbul, Uskudar University". Archived from the original on 2015. Unknown parameter |url-status= ignored (help)
  13. "Second G20 World Brain Mapping Summit at Uskudar University". Unknown parameter |url-status= ignored (help)
  14. 14.0 14.1 Makar, A. B.; McMartin, K. E.; Palese, M.; Tephly, T. R. (June 1975). "Formate assay in body fluids: application in methanol poisoning". Biochemical Medicine. 13 (2): 117–126. doi:10.1016/0006-2944(75)90147-7. ISSN 0006-2944. PMID 1.
  15. Therapeutics, Society for Brain Mapping and (2016-09-04), English: 2016 N20 G20 World Brain Mapping Initiative Program (PDF), retrieved 2020-06-10
  16. Kateb, Babak (2016-12-10). "Editorial: What Is Brain Mapping?". Iranian Journal of Neurosurgery. 2 (3): 6–7. doi:10.18869/acadpub.irjns.2.3.6.
  17. "Neurosurgery Market Watch" (PDF). Retrieved June 10, 2020. Unknown parameter |url-status= ignored (help)
  18. "World Brain Mapping and Therapeutic Initiative: A proposed G20 priority due to Major Impact of the Cost of Neurological Disorders on the World Economy" (PDF). Unknown parameter |url-status= ignored (help)
  19. Makar, A. B.; McMartin, K. E.; Palese, M.; Tephly, T. R. (June 1975). "Formate assay in body fluids: application in methanol poisoning". Biochemical Medicine. 13 (2): 117–126. doi:10.1016/0006-2944(75)90147-7. ISSN 0006-2944. PMID 1.
  20. "Global unity and alliance in Brain Mapping and Therapeutics will be achieved in Germany during the G20 Summit at 4th Annual G20 BRAIN Initiative/Neuroscience-20 symposium" (Press release). Unknown parameter |url-status= ignored (help)
  21. "Global unity and alliance Brain Mapping and Therapeutics will be achieved in Germany during the G20 Summit at 4th Annual G20 BRAIN Initiative/Neuroscience-20 summit". Unknown parameter |url-status= ignored (help)
  22. "4TH ANNUAL G20 BRAIN INITIATIVE/NEUROSCIENCE-20 SYMPOSIUM". Unknown parameter |url-status= ignored (help)
  23. "Special Section Guest Editorial: Brain Mapping and Therapeutics". doi:10.1117/1.NPh.4.1.011001. PMID 28401171. Unknown parameter |url-status= ignored (help)
  24. "DR. ZELINSKY ADDRESSED N20 WORLD SUMMIT Dr. Deborah Zelinsky was recently a keynote speaker at the N20 Summit in Buenos Aires Argentina". Unknown parameter |url-status= ignored (help)
  25. "Üsküdar University Attends G20 5th Brain Initiative / Neuroscience Summit". Unknown parameter |url-status= ignored (help)
  26. "MEGIN CEO Janne Huhtala Speaks At Neuroscience-20 (N20)/G20 World Brain Mapping Summit". Unknown parameter |url-status= ignored (help)
  27. "MEGIN CEO Janne Huhtala Speaks At Neuroscience-20 (N20)/G20 World Brain Mapping Summit". Unknown parameter |url-status= ignored (help)
  28. "N20: Spine in the spotlight at global meeting". Unknown parameter |url-status= ignored (help)
  29. "BATTLING GLOBAL BURDEN OF BRAIN AND SPINE DISORDERS THROUGH TECHNOLOGY, INNOVATION, LOW COST APPROACHES AND BETTER POLICY" (PDF). Unknown parameter |url-status= ignored (help)
  30. "Ontario Tech's Dr. Pierre Côté shares health policy research on the international stage". Unknown parameter |url-status= ignored (help)
  31. "Newsletter MEGIN". Unknown parameter |url-status= ignored (help)
  32. "Economic Burden of Neurological disorders in an aging society (Japan): A panel data analysis" (PDF). ADBI Institute. Unknown parameter |url-status= ignored (help)
  33. "FDA APPROVES CLINICAL TRIAL FOR COVID-19 CELL THERAPY". Unknown parameter |url-status= ignored (help)
  34. "G20 nations to allocate over $21 billion for tackling coronavirus — statement". Unknown parameter |url-status= ignored (help)


This article "Neuroscience 20 (Brain20, Spine20 and Mental Health20)" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Neuroscience 20 (Brain20, Spine20 and Mental Health20). Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.